Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Conditions:   Positive Lymph Node;   Prostate Adenocarcinoma;   PSA Level Greater Than Zero;   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC  v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8 Interventions:   Drug: Abiraterone Acetate;   Drug: Apalutamide;   Drug: Hormone Therapy;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy Sponsors:   NRG Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Publication date: Available online 31 October 2018Source: European UrologyAuthor(s): Daniel J. Canter, Julia Reid, Maria Latsis, Margaret Variano, Shams Halat, Saradha Rajamani, Kristen E. Gurtner, Zaina Sangale, Michael Brawer, Steven Stone, Stephen BardotAbstractBackgroundBetter prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain.ObjectiveTo evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes in a large cohort of men with pr...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Condition:   Prostate Adenocarcinoma Interventions:   Drug: Leuprolide Acetate;   Drug: Goserelin Acetate;   Radiation: Stereotactic Body Radiation Therapy;   Radiation: Radium Ra 223 Dichloride;   Other: Laboratory Biomarker Analysis Sponsor:   City of Hope Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abiraterone Acetate | Adenocarcinoma | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Prednisone | Prostate Cancer | Radiation Therapy | Research